Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/32281
DC FieldValueLanguage
dc.contributor.authorGokengin, Denizen_US
dc.contributor.authorBursa, Dominiken_US
dc.contributor.authorSkrzat-Klapaczynska, Agataen_US
dc.contributor.authorAlexiev, Ivailoen_US
dc.contributor.authorArsikj, Elenaen_US
dc.contributor.authorBalayan, Tateviken_US
dc.contributor.authorBegovac, Josipen_US
dc.contributor.authorCicic, Almaen_US
dc.contributor.authorDragovic, Gordanaen_US
dc.contributor.authorHarxhi, Arjanen_US
dc.contributor.authorAimla, Kerstinen_US
dc.contributor.authorLakatos, Botonden_US
dc.contributor.authorMatulionyte, Raimondaen_US
dc.contributor.authorMulabdic, Velidaen_US
dc.contributor.authorOprea, Cristianaen_US
dc.contributor.authorPapadopoulos, Antoniosen_US
dc.contributor.authorRukhadze, Ninoen_US
dc.contributor.authorSedlacek, Daliboren_US
dc.contributor.authorSojak, Lubomiren_US
dc.contributor.authorTomazic, Janezen_US
dc.contributor.authorVassilenko, Annaen_US
dc.contributor.authorVasylyev, Martaen_US
dc.contributor.authorVerhaz, Antonijaen_US
dc.contributor.authorYancheva, Ninaen_US
dc.contributor.authorYurin, Olegen_US
dc.contributor.authorKowalska, Justynaen_US
dc.date.accessioned2025-01-17T10:38:00Z-
dc.date.available2025-01-17T10:38:00Z-
dc.date.issued2023-01-04-
dc.identifier.issn2076-393X-
dc.identifier.urihttp://hdl.handle.net/20.500.12188/32281-
dc.description.abstractWith no expected vaccine for HIV in the near future, we aimed to define the current situation and challenges for pre- and post-exposure prophylaxis (PrEP and PEP) in Central and Eastern Europe (CEE). The Euroguidelines CEE Network Group members were invited to respond to a 27-item survey including questions on PrEP (response rate 91.6%). PrEP was licensed in 68.2%; 95 centers offered PrEP and the estimated number on PrEP was around 9000. It was available in daily (40.1%), on-demand (13.3%), or both forms (33.3%). The access rate was <1−80%. Three major barriers for access were lack of knowledge/awareness among people who are in need (59.1%), not being reimbursed (50.0%), and low perception of HIV risk (45.5%). Non-occupational PEP was available in 86.4% and was recommended in the guidelines in 54.5%. It was fully reimbursed in 36.4%, only for accidental exposures in 40.9%, and was not reimbursed in 22.72%. Occupational PEP was available in 95.5% and was reimbursed fully. Although PrEP scale-up in the region has gained momentum, a huge gap exists between those who are in need of and those who can access PrEP. Prompt action is required to address the urgent need for PrEP scale-up in the CEE region.en_US
dc.language.isoenen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofVaccinesen_US
dc.subjectHIVen_US
dc.subjectpre-exposure prophylaxisen_US
dc.subjectpost-exposure prophylaxisen_US
dc.subjectCentral and Eastern Europeen_US
dc.titlePrEP Scale-Up and PEP in Central and Eastern Europe: Changes in Time and the Challenges We Face with No Expected HIV Vaccine in the near Futureen_US
dc.typeArticleen_US
dc.identifier.doi10.3390/vaccines11010122-
dc.identifier.urlhttps://www.mdpi.com/2076-393X/11/1/122/pdf-
dc.identifier.volume11-
dc.identifier.issue1-
dc.identifier.fpage122-
item.grantfulltextopen-
item.fulltextWith Fulltext-
Appears in Collections:Faculty of Medicine: Journal Articles
Files in This Item:
File SizeFormat 
PrEP_Scale-Up_and_PEP_in_Central_and_Eastern_Europ (1).pdf619.67 kBAdobe PDFView/Open
Show simple item record

Page view(s)

35
checked on May 3, 2025

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.